Larimar Therapeutics (LRMR) Cash from Investing Activities Growth (3y) (2016 - 2024)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Cash from Investing Activities Growth (3y) (2016 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -39.19% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -177.73% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 46.78% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 66.14% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -44.69% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -246.81% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -72.08% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 27.84% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 43.55% |
| Sep 30, 2024 | 81.87% |
| Jun 30, 2024 | -74.39% |
| Mar 31, 2024 | -146.73% |
| Dec 31, 2023 | 51.85% |
| Sep 30, 2023 | -1,697.09% |
| Jun 30, 2023 | -30.79% |
| Mar 31, 2023 | 394.03% |
| Dec 31, 2022 | -914.68% |
| Dec 31, 2021 | -23.09% |
| Sep 30, 2021 | 47.69% |
| Jun 30, 2021 | 32.06% |
| Mar 31, 2021 | -33.63% |
| Dec 31, 2020 | -56.80% |
| Sep 30, 2020 | -26.59% |
| Jun 30, 2020 | 43.60% |
| Mar 31, 2020 | -27.84% |
| Dec 31, 2019 | -26.05% |
| Jun 30, 2019 | -30.45% |
| Mar 31, 2019 | -61.62% |